JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117.
Latest Ratings for RARE
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Morgan Stanley | Maintains | Overweight | |
| Feb 2022 | JP Morgan | Upgrades | Neutral | Overweight |
| Feb 2022 | Morgan Stanley | Maintains | Overweight |
